Cagrilintide

Cagrilintide is an investigational drug, not yet approved by regulatory bodies like the FDA, 
primarily studied for its benefits in weight management and improved glycemic control.
Prospective benefits:

• Significant Weight Loss: As a monotherapy in Phase 3 trials, cagrilintide resulted 
in an average body weight reduction of approximately 11.8% over 68 weeks. 
When combined with semaglutide (a combination known as CagriSema), the 
weight loss was even more substantial, with participants achieving a mean 
weight reduction of over 20% in clinical trials.

• Appetite and Satiety Control: Cagrilintide is a long-acting analog of the natural 
hormone amylin, which is secreted by the pancreas alongside insulin.                                            It works by:  Slowing gastric emptying, which helps individuals feel full faster and for 
longer periods after meals.  Activating appetite-regulating centers in the brain, which helps reduce hunger and cravings, leading to lower overall caloric intake.

• Improved Glycemic Control: Cagrilintide helps to regulate post-meal blood sugar 
levels by suppressing glucagon secretion. 

• Cardiometabolic Health Improvements: The weight loss and improved metabolic 
function associated with cagrilintide therapy con åtribute to broader health 
benefits, including reductions in blood pressure, improved cholesterol and 
triglyceride levels, and a decrease in inflammatory markers